ONCAlert | 2017 San Antonio Breast Cancer Symposium

Potential for Glembatumumab Vedotin in TNBC

Linda T. Vahdat, MD, PhD
Published Online: 7:25 PM, Thu December 8, 2016


Linda T. Vahdat, MD, PhD, ‎Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.